Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Obesity Weight Loss, Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 2/9/2019 |
| Start Date: | October 16, 2017 |
| End Date: | May 20, 2019 |
A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity
This study looks at a new study medicine for weight management in people with overweight or
obesity. The aim of this study is to find out how safe and tolerable the study medicine is.
The study also looks at how the study medicine behaves in the body and how it is removed from
the body.
Participants will either get NNC9204-1177 (the new study medicine) or placebo (a formula that
looks like the study medicine but does not have active ingredients). Which treatment
participants get will be decided by chance.
NNC9204-1177 has not been approved by the United States Food and Drug Administration. Its use
in this study is experimental. Participants will get 1 or more injections into the skin of
the stomach area once each week for 12 weeks.
The study will last for about 5 months. Participants will have 19 clinic visits with the
study doctor. At certain times during the study, participants will have blood draws and 3
different kinds of electrocardiograms. Participants will answer mental health questionnaires.
Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during
the study period.
obesity. The aim of this study is to find out how safe and tolerable the study medicine is.
The study also looks at how the study medicine behaves in the body and how it is removed from
the body.
Participants will either get NNC9204-1177 (the new study medicine) or placebo (a formula that
looks like the study medicine but does not have active ingredients). Which treatment
participants get will be decided by chance.
NNC9204-1177 has not been approved by the United States Food and Drug Administration. Its use
in this study is experimental. Participants will get 1 or more injections into the skin of
the stomach area once each week for 12 weeks.
The study will last for about 5 months. Participants will have 19 clinic visits with the
study doctor. At certain times during the study, participants will have blood draws and 3
different kinds of electrocardiograms. Participants will answer mental health questionnaires.
Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during
the study period.
Inclusion Criteria:
- Male or female, aged 18-55 years (both inclusive) at the time of signing informed
consent
- Body mass index (BMI) between 27.0 and 39.9 kg/m2 (both inclusive) at screening.
Overweight should be due to excess adipose tissue, as judged by the investigator
Exclusion Criteria:
- Any disorder which in the investigator's opinion might jeopardise subject's safety,
evaluation of results, or compliance with the protocol
- Subjects, aged at least 40 years, with an estimated 10-year atherosclerotic
cardiovascular disease (ASCVD) risk greater than or equal to 5%
- Male subjects who are not sexually abstinent or surgically sterilised (vasectomy) and
are sexually active with female partner(s) who are not using a highly effective method
of contraception (such as condom with spermicide) combined with a highly effective
method of contraception for their non-pregnant female partner(s) (Pearl Index below
1%, such as implants, injectables, oral contraceptives, intrauterine devices,
diaphragm or cervical cap+spermicide), or who intend to donate sperm in the period
from screening until 3 months following last administration of the investigational
medical product
- Female subjects who are of child bearing potential (pre-menopausal and not surgically
sterilised) and are sexually active with male partner(s) who are not surgically
sterilised (vasectomy) and who are not using highly effective contraceptive methods
(Pearl Index below 1%, such as implants, injectables, oral contraceptives,
intrauterine devices, diaphragm or cervical cap+spermicide) combined with a highly
effective method of contraception for their male partner(s) (e.g. condom with
spermicide), or who are pregnant, breast-feeding or intend to become pregnant
We found this trial at
1
site
Click here to add this to my saved trials
